George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Last chance for those that really want to probe GM. Go on why not make him sweat for his millions.
Quite simply there is not enough clarity here. We spent months without forward guidance.
Now there is still no clarity re. what exactly Ncyt is going to do. Testing. Instrumentstion. Products are specified. Apart from NHS …little clarity re contracts or 2021/2022 direction. Much usual beneer about privilege and hard work etc etc as is usually said. So much so that it becomes meaningless.
Precise markets??
Targeted countries ( outside US and that fell!)
Very little was actually said. Just reiteration of products and humungous writedown numbers that engulfed profit.
And what are they aiming to do withbthe 77m cash? And the share buyback? How effective? We are at same s/p as March 2020. How can they justify this??
Doninvestors come into their listvof priorities or even discussions? I think not.
Director buys please. Not share buybacks. Become an investor in your own company. With a long term incentive plan to keep you on the ball so that you have to care.
Can’t see it.
Salaries ? Bonuseses? Nice number if you get there.
Every RNS paints a bleaker picture. Followed by a hint of almost but not quite apologetic rhetoric.
Seems almost just a paper exercise to be gotten out of the way.
I do hope people have the wherewithall to ask real(!!) questions to the BOD.
The share price means JS to Novacyt. It looks like 9 months to me before any investorvprogress will be shown.
5 years is too long Kitzie. We need to start doing both in the next 12 months. Nothing wrong with acquiring non-covid businesses and then using our cash pile that is currently sat doing nothing, to help them grow. Lots of synergies that Ncyt can leverage.
Beyond Covid may be some time yet with almost 38K infections Sunday this company should be making money fast
"Appointment of US General Manager and set-up of Novacyt US Inc"
I would use investment and build around this potential....uptake is so much faster over in the USA, especially with innovation....then NCYT would hit the radar of many and be stratigically positioned for a handsome buyout.
Kitzie I do not disagree but with the amount of cash the company is sitting on and the amount of new employees they need to do both in tandem and I am very interested to learn more about new non covid products / acquisitions .
.......it's time this board got a grip and sorts out it's priorities.....if you're not happy invested here, sell up and move on, stop the personal attacks and keep to the research that's proactive or constructive
this pandemic disaster has hit the world like nothing else in the past 50 years!....whomever thinks that it over and business will stop after this Winter, needs their head looking at....this country can't even prepare for a shortfall in drivers that they could have averted and planned for, yet the petrol stations have run out......and you think we're done and able to manage and plan for the future for variant and all types of viruses to come......you must be having a laugh!
the short, medium and long term is still very much COVID and prevention of future mass lockdowns by correct screening and vaccine development by adequate variant data collection from precise testing is the priority. OK, some sideline projects will happen, but 99% of resources must continue with COVID/ FLU/ RSV for the foreseable future at least....5++ years minimum...whom are you trying to kid otherwise
Agree BH2 and if he doesn't give a steer fairly quickly then I am sure he will hear from many of us , myself included.
All in good time I think levin -
I can see where you are coming from, but I also see that DA is the guy to make certain calls when appointed.
There ain't no answers before then IMO.
I had a skim through of the results now but couldn’t see anything to do with non-covid revenues. Did anyone else get a glimpse of what they are planning to do with the 300 odd staff they now have with relaxations happening across the world ? For me that is the more concerning part . There were talk of covid plus and respiratory diseases strategy but it’s about time they move into the plan. They need to beat the 100 mil H1 2021 results in H1 2022 to create sustainable SP growth and P/E rerates . I don’t think they will hit it without diversifying.